

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

**Claim 1 (Currently Amended):** A protein comprising:

a first functional unit of a first complement regulatory protein, ~~wherein the first functional unit exhibits complement-regulating properties~~ wherein the first functional unit comprises CCPs 2, 3 and 4 of DAF;

a first spacer sequence of at least about 200 amino acids ~~encoding a polypeptide that~~ , wherein the first spacer sequence does not exhibit complement regulating properties, attached to the first functional unit; and

a second functional unit attached to the spacer sequence, selected from the group consisting of ~~polypeptides providing a functional unit of a second complement regulatory protein, polypeptides derived from an immunoglobulin, and polypeptides that enhance binding of the protein to an animal cell~~ CCPs 8-10 of Complement Receptor 1 (CR1), CCPs 15-17 of CR1, poly peptides derived from Fc fragments of IgG4, and a lipid tail.

**Claim 2 (Currently Amended):** The protein of claim 1, additionally comprising a second spacer sequence of at least about 200 amino acids ~~encoding a polypeptide~~ that does not exhibit complement regulating properties attached to the second function domain, and a third functional unit attached to the second spacer, wherein the third functional unit is selected from the group consisting of polypeptides

derived from an immunoglobulin Fc fragments of IgG4, and polypeptides that enhance binding of the protein to an animal cell a lipid tail.

**Claim 3 (Cancelled):**

**Claim 4 (Cancelled):**

**Claim 5 (Previously Presented):** The protein of claim 1, wherein the spacers are selected from the group consisting of substantially all of the amino acids of CCPs 4-7 of CR1, and substantially all of the amino acids of CCPs 11-14 of CR1.

**Claim 6 (Cancelled)**

**Claim 7 (Currently Amended):** The protein of claim 6 1, additionally comprising a second spacer comprising substantially all of the amino acids of CCPs 4-5 of CR1, and a third functional unit selected from the group consisting of CCPs 8-10 of CR1, CCPs 1-4 of MCP, and polypeptides derived from Ig-G4 Fc fragments of IgG4.

**Claim 8 (Withdrawn):** A polynucleotide encoding the protein of claim 6.

**Claim 9 (Withdrawn):** A polynucleotide encoding the protein of claim 7.

**Claim 10 (Withdrawn):** A polynucleotide encoding the protein of claim 1.

**Claim 11 (Withdrawn):** A vector comprising the polynucleotide of claim 10.

**Claim 12 (Currently Amended):** A protein having an amino acid sequence that is at least 95 percent ~~sequence-homology~~ homologous to a protein selected from the group consisting of proteins having the sequence of SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 19, and SEQ ID NO: 23.

**Claim 13 (Withdrawn):** A polynucleotide encoding the protein of claim 12.

**Claim 14 (Currently Amended):** A method of regulating inhibiting complement activity comprising administering an effective amount of protein of ~~claim 4~~ to a mammal the protein having an amino acid sequence that is at least 95 percent homologous to a protein selected from the group consisting of proteins having the sequence of SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 19, and SEQ ID NO: 23.

**Claim 15 (Previously Presented):** The method of claim 14, wherein the mammal is a human.

**Claim 16 (Cancelled)**

**Claim 17 (Cancelled)**

**Claim 18 (Cancelled)**

**Claim 19 (New):** The method of claim 14, the protein being selected from the group consisting of proteins having the sequence of SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO:19, and SEQ ID NO:23.

**Claim 20 (New):** The method of claim 14, the protein being selected from the group consisting of proteins having the sequence of SEQ ID NO: 13 and SEQ ID NO: 15.